GALMED PHARMACEUTICALS LTD

GALMED PHARMACEUTICALS LTD

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty li... ver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd_logo
Social Links:

Industry:
Company

Founded:
2000

Address:
16 Tiomkin Street, Tel Aviv, Israel Zipcode 6578317

Country:
Israel

Phone:
972 3 693 8448

Market Cap:
82.45M
Total Assets:
52.38M
Total Cash:
6.95M

Chairman: Allen Baharaff


Key Executives
Name Title Pay Year Born
Mr. Allen Baharaff Co-Founder, Pres, CEO & Chairman 766,583$ 1965(55 years old)
Mr. Yohai Stenzler Chief Financial Officer 167,265$ 1983(37 years old)
Mr. Guy Nehemya Chief Operating Officer 167,545$ 1985(35 years old)
Dr. Liat Hayardeny Chief Scientific Officer 215,449$ 1967(53 years old)
Dr. Tali Gorfine Medical Consultant 202,763$ 1970(50 years old)
Ms. Yael Hollander VP of Legal Affairs & Strategy N/A 1983(37 years old)



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state REGULAR
According to Galmed Pharmaceuticals Ltd's financial reports the company's revenue in 2020 were 0 an decrease(NAN%) over the years 2019 revenue that were of 0. In 2020 the company's total earnings were -28.77M while total earnings in 2019 were -20.46M( +40%).
Company's stock symbol is GLMD. Lastest price : 3.2868. Total volume :114.09k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.galmedpharma.com

  • Host name: 192.252.154.40
  • IP address: 192.252.154.40
  • Location: Waltham United States
  • Latitude: 42.3972
  • Longitude: -71.2434
  • Metro Code: 506
  • Timezone: America/New_York
  • Postal: 02451

Loading ...
Loading ...


More informations about "Galmed Pharmaceuticals Ltd" on Search Engine

Company Profile - Galmed Pharmaceuticals

Galmedpharma.com Galmed Pharmaceuticals Ltd. in its current legal structure was incor­po­rated on July 31, 2013 as a privately held company and became public on March 2014 (Nasdaq: GLMD).

Galmed Pharmaceuticals - Biopharmaceutical Company

Galmedpharma.com This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website.

Galmed Pharmaceuticals Ltd. (GLMD) Company Profile & Facts

Finance.yahoo.com Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

Galmed Pharmaceuticals Ltd. (GLMD) Stock Price, News

Finance.yahoo.com Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral...

Investors Center - Galmed Pharmaceuticals

Galmedpharma.investorroom.com Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results Mar 16, 2021 Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER

Galmed Pharmaceuticals Ltd - Company Profile and News

Bloomberg.com Galmed Pharmaceuticals Ltd. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatment of liver diseases and cholesterol gallstones.

News - Galmed Pharmaceuticals

Galmedpharma.investorroom.com Mar 18, 2021 · Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator,... Feb 16, 2021 Galmed Pharmaceuticals Announces Pricing of …

GLMD Stock Price | Galmed Pharmaceuticals Ltd. Stock Quote

Marketwatch.com Apr 09, 2021 · Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH).

GLMD Stock Forecast, Price & News (Galmed Pharmaceuticals)

Marketbeat.com Jan 19, 2021 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings data on Wednesday, March, 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.12. View Galmed Pharmaceuticals' …

GLMD Galmed Pharmaceuticals Ltd. — Stock Price and

Stocktwits.com Apr 09, 2021 · Galmed Pharmaceuticals Ltd. NASDAQ Updated Apr 9, 2021 9:25 PM GLMD 3.37 0.07 (2.12%). Post-Market 0.04 (1.19%)

Galmed Pharmaceuticals Announces Proposed Offering of

Ih.advfn.com Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

Galmed Pharmaceuticals Provides Business Update and

Prnewswire.com Mar 18, 2021 · GALMED PHARMACEUTICALS LTD. Consolidated Statements of Cash Flows (Audited) U.S. Dollars in thousands. Year ended December 31, 2020. 2019. 2018. Cash flow …

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on

Seekingalpha.com Mar 18, 2021 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants. Allen Baharaff - President & …

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Receives

Themarketsdaily.com Mar 24, 2021 · Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

GLMD | Galmed Pharmaceuticals Ltd. Profile | MarketWatch

Marketwatch.com Mar 29, 2021 · Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of …

Galmed Pharmaceuticals Ltd. | LinkedIn

Linkedin.com Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate...

GLMD:NASDAQ CM Stock Quote - Galmed Pharmaceuticals Ltd

Bloomberg.com Galmed Pharmaceuticals Ltd. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatment of liver diseases and cholesterol gallstones. Galmed...

The Chart for Galmed Pharmaceuticals Ltd. (GLMD) Is

Newsheater.com Feb 12, 2021 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) went up by 22.45% from its latest closing price compared to the recent 1-year high of $6.40. The company’s stock price has collected 14.16% of gains in the last five trading sessions. Press Release reported on 01/26/21 that Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting …

GLMD | Galmed Pharmaceuticals Ltd. Stock Price & News - WSJ

Wsj.com View the latest Galmed Pharmaceuticals Ltd. (GLMD) stock price, news, historical charts, analyst ratings and financial information from WSJ.

GLMD - Galmed Pharmaceuticals Ltd. • BioPharmCatalyst

Biopharmcatalyst.com About Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

GLMD | Galmed Pharmaceuticals Ltd. Analyst Estimates

Wsj.com Galmed Pharmaceuticals Ltd. analyst ratings, historical stock prices, earnings estimates & actuals. GLMD updated stock price target summary.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Expected to

Themarketsdaily.com Mar 12, 2021 · Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It …

Galmed Pharmaceuticals Ltd. Stock Price (GLMD) | Barron's

Barrons.com Jun 05, 2020 · View today's stock price, news and analysis for Galmed Pharmaceuticals Ltd. (GLMD). Barron's also provides information on historical stock ratings, target prices, company earnings, market ...

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest

Marketbeat.com Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD) Stock

Nasdaq.com Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Galmed Pharmaceuticals Ltd (GLMD : NASDAQ) Stock Price

Google.com Get the latest Galmed Pharmaceuticals Ltd (GLMD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

GLMD.OQ - Galmed Pharmaceuticals Ltd Profile | Reuters

Reuters.com About Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on …

GLMD: Galmed Pharmaceuticals Ltd - Stock Price, Quote and

Cnbc.com Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript March 18, 2021 Seeking Alpha. Profile MORE. Galmed Pharmaceuticals is …

GLMD Galmed Pharmaceuticals Ltd. Stock Quote

Elite.finviz.com Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

Galmed Pharmaceuticals Ltd - Home | Facebook

Facebook.com Galmed Pharmaceuticals Ltd, Tel Aviv, Israel. 1,048 likes · 3 were here. Galmed Pharmaceuticals Ltd. in its current legal structure was incorporated on July 31, 2013 as a privately held company.

Galmed Pharmaceuticals Ltd. - Company Profile - BCIQ

Bciq.biocentury.com Nov 03, 2018 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Tel Aviv, Israel Business: Hepatic, Gastrointestinal Date completed: 2016-09-29 Type: Private placement Raised: $4.8 million Shares: 933,160 Price: $5.11 Shares after offering: 12 million Placement agent: …

Should I buy Galmed Pharmaceuticals Ltd. (GLMD) - Zacks

Zacks.com Feb 19, 2021 · Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv ...

-$0.36 EPS Expected for Galmed Pharmaceuticals Ltd

Theenterpriseleader.com Mar 21, 2021 · Analysts forecast that Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will post earnings of ($0.36) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galmed Pharmaceuticals’ earnings. Galmed Pharmaceuticals posted earnings per share of ($0.29) during the same quarter last year, which would indicate a …

Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing

Fool.com Jun 12, 2018 · Why Galmed Pharmaceuticals Ltd. Stock Is Skyrocketing Today Investors are cheering Galmed's experimental NASH drug, causing the biotech's shares to more than triple in value.

Galmed Pharmaceuticals Announces Pricing of $10 Million

Ih.advfn.com Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Significant

Theenterpriseleader.com Feb 17, 2021 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a large growth in short interest in the month of January. As of January 29th, there was short interest totalling 37,800 shares, a growth of 49.4% from the January 14th total of 25,300 shares. Based on an average trading volume of 155,400 shares, the short-interest ratio is […]

Galmed Pharmaceuticals Ltd (GLMD) Stock: How Does it Score?

Investorsobserver.com Galmed Pharmaceuticals Ltd stock is down -27.23% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives GLMD stock a score of 66 out of a possible 100.. That rank is mainly influenced by a fundamental score of 99. In addition to the average rating from Wall Street analysts, GLMD stock has a mean target ...

Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD) Pre

Nasdaq.com Galmed Pharmaceuticals Ltd. Ordinary Shares (GLMD) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Galmed Pharmaceuticals Ltd. - GLMD - Stock Price Today - Zacks

Zacks.com Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd…

Galmed Pharmaceuticals Ltd Stock Price Today (NASDAQ: GLMD)

Wallstreetzen.com Apr 05, 2021 · Galmed Pharmaceuticals Ltd. stock was originally listed at a price of $14.31 in Mar 13, 2014. If you had invested in Galmed Pharmaceuticals Ltd stock at $14.31 , your return over the last 7 years would have been -76.17% , for an annualized return of -18.53% .

Galmed Pharmaceuticals Ltd (GLMD) Quote - XNAS | Morningstar

Morningstar.com Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol ...

Before Buying Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)

Stocksregister.com Mar 20, 2021 · Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shares, rose in value on Friday, Mar 19, with the stock price up by 14.62% to the previous day’s close as strong demand from buyers drove the stock to $3.92. Get the hottest stocks to trade every …

GALMED PHARMACEUTICALS LTD. : GLMD Stock Price

Marketscreener.com Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases.

Galmed Pharmaceuticals Ltd Stock Forecast & Predictions

Wallstreetzen.com Galmed Pharmaceuticals Ltd 's earnings in 2021 is -$20,461,000.On average, 3 Wall Street analysts forecast GLMD's earnings for 2021 to be $-32,720,151, with the lowest GLMD earnings forecast at $-34,260,838, and the highest GLMD earnings forecast at $-30,057,054.

Galmed Pharmaceuticals Ltd. - AnnualReports.com

Annualreports.com Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase III registrational study.

Galmed Pharmaceuticals Ltd, GLMD:NAQ summary - FT.com

Markets.ft.com Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceut icals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic ...

Galmed Pharmaceuticals Ltd. to Host Earnings Call | Benzinga

Benzinga.com Mar 18, 2021 · NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18 ...